Enhancing the efficiency of oncolytic vaccinia virus for ovarian cancer treatment
Vaccinia virus, known for its clinical safety has a tropism for primary and metastatic tumours as well as ovarian tissue. Consequently, oncolytic approaches with recombinant vaccinia viruses have emerged as attractive agents against ovarian cancer. Unfortunately, oncolytic vaccinia monotherapies are yet to live up to their potential promise. Given this, there is a need to identify combination agents that improve the effectiveness of vaccinia in ovarian cancer treatment. We screened 9,000 compounds to identify drugs that enhance the ability of a recombinant vaccinia virus lacking VGF and F1 ({Delta}VF) to induce death of ID8 Trp53-/- murine ovarian cancer cells. We identified a class of tubulin polymerisation inhibitors including vinorelbine. The combination of vinorelbine and vaccinia induces ID8 Trp53-/- cell death via apoptosis. In a syngeneic mouse model of high grade serous ovarian carcinoma, {Delta}VF virus lacking the viral thymidine kinase (TK), armed with GM-CSF and expressing NeonGreen ({Delta}VFTK-NG-GM-CSF) is tumour specific. A combination of the {Delta}VFTK-NG-GM-CSF virus with vinorelbine prolongs mouse survival compared to the treatment of mice with either agent alone. Our study suggests vinorelbine is a promising agent to combine with oncolytic vaccinia virus approaches for the management of ovarian cancer.